Christopher Garabedian is the President and CEO of Sarepta Therapeutics, a company focused on developing therapies for rare diseases like Duchenne Muscular Dystrophy (DMD). He took over as CEO in January 2011 after being appointed to the board in 2010....
Christopher Garabedian is the President and CEO of Sarepta Therapeutics, a company focused on developing therapies for rare diseases like Duchenne Muscular Dystrophy (DMD). He took over as CEO in January 2011 after being appointed to the board in 2010. Garabedian has an MBA from Harvard Business School, which shows he's got a solid business foundation. Before joining Sarepta, he played key roles at Celgene and Gilead Sciences, giving him a strong background in the pharmaceutical industry. His leadership style is hands-on. He emphasizes aligning the company’s goals with long-term shareholder interests, indicating that he thinks strategically about the future. During his time at Sarepta, he earned a total compensation of about $979,000 in 2016, with a significant cash bonus for achieving corporate goals. Garabedian demonstrated confidence in the company by holding substantial stock options, which highlights his belief in Sarepta's mission. His track record includes guiding Sarepta through critical trial phases, especially with the drug eteplirsen, which was pivotal for DMD patients. Overall, he has been a significant figure in pushing the biotechnology field forward, especially in developing treatments for genetic disorders.